The UAE will retain its position as an attractive market for innovative drugmakers due to the population's preference for patented drugs, high per capita expenditure on pharmaceuticals and continued government investment in the healthcare sector. Pharmaceutical companies with product portfolios geared towards the treatment of chronic diseases will be provided with a rapidly expanding patient base. However, we highlight that medicine price cuts throughout the Gulf Cooperation Council states will become more frequent, dampen ing profit margins for innovative drugs.
Headline Expenditure Projections
* Pharmaceuticals: AED8.14bn (USD2.22bn) in 2013 to AED8.30bn (USD2.26bn) in 2014; +2.0% in local currency and US dollar terms. Forecast adjusted from last quarter to better suit current market conditions.
* Healthcare: AED42.68bn (USD11.62bn) in 2013 to AED44.93bn (USD12.24bn) in 2014; +5.3% in local currency terms and +5.4% US dollar terms. Forecast revised downward from last quarter to better suit current market conditions.
Full Report Details at
- http://www.fastmr.com/prod/944665_united_arab_emirates_pharmaceuticals_healthcare.aspx?afid=101
Risk/Reward Index
In our Q414 Pharmaceutical Risk/Reward Index (RRI), the UAE scores 58.6 and is ranked second out of a total of 31 markets in our Middle East and Africa regional matrix.
Key Trends & Developments
November 2014
* The Dubai Health Authority (DHA) imposed a price cap on the cost of health services in Dubai, which is expected to bring a sustainable synergy between healthcare providers and patients' interests. The DHA has set a 4.2% limit for 2015 effective from January 1, to ensure that healthcare providers do not exploit the free market principles. The cap is not a price-fixing measure but a regulatory mechanism aimed to balance supply and demand, according to the DHA. Under the new policy, the DHA will investigate the validity and purpose of each price increase application by a healthcare provider on a single service-by-service basis, as opposed to a blanket hike. The DHA will also impose severe penalties on violators...
The United Arab Emirates Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's United Arab Emirates Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the United Arab Emirates pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's pharmaceutical and healthcare market forecasts for United Arab Emirates, to test other views - a key input for successful budgeting and strategic business planning in the Emirati pharmaceutical and healthcare market.
* Target business opportunities and risks in the Emirati pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in United Arab Emirates.
* Assess the activities, strategy and market position of your competitors via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
Coverage
BMI Industry ViewAn at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.
BMI Industry Forecast ScenarioIndustry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:
Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).Patented Drug Market: Prescription drug sales (USDbn & % of total sales).Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).OTC Drug Market: OTC sales (USDbn & % of total sales).Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward IndexBMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.
Market SummaryA snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape
Industry DevelopmentsA focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
Regulatory RegimeDetails of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.
Competitive LandscapeThe competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
read full article